Recursion Pharmaceuticals, Inc. - Class A Common Stock (NQ:RXRX)

4.120 +0.050 (+1.23%)

Delayed Quote Updated: 4:00 PM EDT, Oct 2, 2026 Add to My Watchlist

Quote

Overview Detailed Quote Charting Historical Prices

News

All News News Headlines Press Releases

Research

Quarterly Reports Insider Filings Other Filings

All News about Recursion Pharmaceuticals, Inc. - Class A Common Stock

< Previous 1 2

...

5 6 7 8 9 10 11 12 13

...

23 24 Next >

Altitude Lab Launches Pre-seed Venture Fund, Anchored by Recursion CEO Chris Gibson, Enabling SBIR-awarded Biotechs Hit by Funding Gap to Build in Salt Lake City

February 19, 2025

The Altitude Lab Fund aims to deliver strong returns to Limited Partners, accelerate the growth of Salt Lake City’s Life Science hub, and enable high potential startups support while federal funding is...

From Recursion Pharmaceuticals

Via GlobeNewswire

Watsco Posts Upbeat Results, Joins GeneDx, Intel And Other Big Stocks Moving Higher On Tuesday ↗

February 18, 2025

Via Benzinga

25 Top AI Stocks That Could Boost Your Portfolio ↗

February 18, 2025

Via The Motley Fool

Topics Artificial Intelligence

Where Recursion Pharmaceuticals Stands With Analysts ↗

February 06, 2025

Via Benzinga

Altitude Lab Startups Raise $154M in Capital

February 18, 2025

The Accelerator Awards $150,000 Fellowship to Elnora AI CEO, and Announces Key Cohort Milestones

From Recursion Pharmaceuticals

Via GlobeNewswire

SoftBank Joins Nvidia In Backing Recursion Pharma, Retail Traders Rally Behind Stock Surge ↗

February 18, 2025

The Japanese conglomerate’s bet comes amid growing AI sector momentum, fueled in part by chipmaking giant Nvidia, which also holds over 7.7 million Recursion shares.

Via Stocktwits

Topics Artificial Intelligence

WeRide, CRISPR And GeneDx Are Among Top 10 Mid-Cap Gainers Last Week (Feb 10-Feb 14): Are The Others In Your Portfolio? ↗

February 16, 2025

Top performing mid-cap stocks last week: WRD (+97.62%), GDS (+43.45%), SWTX (+42.58%), RXRX (+40.59%), SOC (+39.09%), WGS (+28.23%), VNET (+28.22%), NSP (+25.99%), CRSP (+25.21%), AXSM (+24.01%)

Via Benzinga

How Is The Market Feeling About Recursion Pharmaceuticals? ↗

January 30, 2025

Via Benzinga

Is Recursion Pharmaceuticals Stock a Buy? ↗

January 17, 2025

Via The Motley Fool

10 Health Care Stocks With Whale Alerts In Today's Session ↗

February 14, 2025

Via Benzinga

Why Recursion Pharmaceuticals Stock Is Soaring Today ↗

February 14, 2025

Via The Motley Fool

Nvidia Invests in These 2 Artificial Intelligence (AI) Stocks and Sells These 3 Others ↗

February 14, 2025

Nvidia's 13F revealed some interesting choices.

Via The Motley Fool

Topics Artificial Intelligence

Why SoundHound AI and Serve Robotics Stock Crashed on Friday ↗

February 14, 2025

Via The Motley Fool

Topics Artificial Intelligence

Nvidia Dumps SoundHound, Trims Arm Stake, Buys These 2 Stocks ↗

February 14, 2025

Nvidia disclosed in a regulatory filing Friday that it sold off three tech stocks and added stakes in two others. Nvidia stock rose.

Via Investor's Business Daily

Is Recursion Pharmaceuticals Stock a Millionaire Maker? ↗

December 21, 2024

Via The Motley Fool

Biotechs on the Brink: 2 Stocks With Huge Potential

February 14, 2025

BriaCell Therapeutics and Recursion Pharmaceuticals are two biotech firms that may be poised for success in 2025; risk-tolerant investors might keep an eye out.

Via MarketBeat

Why Coherent Shares Are Trading Higher By Over 15%; Here Are 20 Stocks Moving Premarket ↗

February 06, 2025

Via Benzinga

Recursion Presents Phase 2 Data for REC-994 in CCM in Late-Breaking Oral Presentation at the International Stroke Conference

February 05, 2025

From Recursion Pharmaceuticals, Inc.

Via GlobeNewswire

3 Monster Stocks to Hold for the Next 10 Years ↗

February 01, 2025

A handful of companies are in the right place at the right time with the right product or service.

Via The Motley Fool

AI Pharma: 2 Paths to AI-Powered Drug Investment

January 28, 2025

AI is transforming drug development, allowing companies to identify new drug targets, optimize clinical trials and speed delivery of medicines to patients.

Via MarketBeat

Topics Artificial Intelligence

Nvidia-Backed Recursion Pharma Hits 3-Week High, Sparks Retail Buzz Amid Broader AI Hype ↗

January 22, 2025

The AI chipmaker’s $50 million investment in Recursion, unveiled in 2023 to support AI-driven drug discovery, has been a key driver of investor interest.

Via Stocktwits

Topics Artificial Intelligence

Seagate Posts Upbeat Earnings, Joins Netflix, Travelers, Teledyne Technologies And Other Big Stocks Moving Higher On Wednesday ↗

January 22, 2025

Via Benzinga

2 Growth Stocks That Could Rocket Higher in the First Quarter of 2025 ↗

January 21, 2025

Via The Motley Fool

AI Drug Discovery Startups: Analysis Of Exscientia’s Acquisition By Recursion ↗

January 18, 2025

Exscientia is a European player looking to make a difference in the AI-drug discovery market. Like other players, it has an interesting story to tell. After a brief listing on the stock market,...

Via Talk Markets

Topics Artificial Intelligence Stocks / Equities

Cathie Wood's Ark Invest Loads Up On Intellia Therapeutics Which Laid Off Over A Quarter Of Its Workforce ↗

January 11, 2025

Ark Invest, led by Cathie Wood, made significant trades in 5 companies on Friday: RXRX, ILMN, NTLA, NET, and ADPT.

Via Benzinga

Topics Workforce

AI Drug Discovery Stocks: Recursion Pharmaceuticals Has A Long Road Ahead ↗

January 07, 2025

Among the various use-cases for AI, healthcare has been one of the interesting ones. Recursion Pharmaceuticals (RXRX) is one such notable player in the industry that has successfully leveraged AI in...

Via Talk Markets

Topics Artificial Intelligence Stocks / Equities

Recursion Announces Two Key Investigational Oncology Drugs Advancing to Clinical Trials, Targeting High Unmet Needs in Hematologic Malignancies, Small-Cell Lung Cancer, & More

January 07, 2025

From Recursion Pharmaceuticals

Via GlobeNewswire

Recursion to Present at 43rd Annual JP Morgan Healthcare Conference

January 06, 2025

From Recursion Pharmaceuticals

Via GlobeNewswire

Cathie Wood's Ark Invest Books Profits On Hot AI Stock Palantir, Sells Bitcoin ETF Shares As BTC Starts 2025 On A Positive Note ↗

January 04, 2025

On Friday, Cathie Wood-led Ark Invest made significant trades involving PLTR, ARKB, and QSI. The PLTR trade sold shares worth $1.6 million, aligning with Ark's trend of reducing their position in the...

Via Benzinga

Topics Artificial Intelligence ETFs

Nio, Unity Software And Other Big Stocks Moving Higher On Thursday ↗

January 02, 2025

Via Benzinga

< Previous 1 2

...

5 6 7 8 9 10 11 12 13

...

23 24 Next >

Stock Quote API & Stock News API supplied by www.cloudquote.io. Quotes delayed at least 20 minutes. Market data may be delayed. Research information, not personalized advice.